Critical illness myopathy after COVID-19
- PMID: 32763444
- PMCID: PMC7403134
- DOI: 10.1016/j.ijid.2020.07.072
Critical illness myopathy after COVID-19
Abstract
This paper describes a patient who developed diffuse and symmetrical muscle weakness after a long stay in the intensive care unit (ICU) due to coronavirus disease 2019 (COVID-19). The patient underwent a neurophysiological protocol, including nerve conduction studies, concentric needle electromyography (EMG) of the proximal and distal muscles, and direct muscle stimulation (DMS). Nerve conduction studies showed normal sensory conduction and low-amplitude compound muscle action potentials (CMAPs). EMG revealed signs of myopathy, which were more pronounced in the lower limbs. The post-DMS CMAP was absent in the quadriceps and of reduced amplitude in the tibialis anterior muscle. Based on these clinical and neurophysiological findings, a diagnosis of critical illness myopathy was made according to the current diagnostic criteria. Given the large number of patients with COVID-19 who require long ICU stays, many are very likely to develop ICU-acquired weakness, as did the patient described here. Health systems must plan to provide adequate access to rehabilitative facilities for both pulmonary and motor rehabilitative treatment after COVID-19.
Keywords: Direct muscle stimulation; Electromyography; ICU-acquired weakness; Rehabilitation; SARS-CoV-2.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Comment in
-
SARS-CoV-2-associated critical ill myopathy or pure toxic myopathy?Int J Infect Dis. 2020 Dec;101:56. doi: 10.1016/j.ijid.2020.09.1463. Epub 2020 Sep 28. Int J Infect Dis. 2020. PMID: 33002612 Free PMC article. No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
